The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT

Bone Marrow Transplantation

Volumn 49, Issue 1, 2014, Pages 55-61

  Marek, A ^a   Stern, M ^b   Chalandon, Y ^c   Ansari, M ^c   Ozsahin, H ^c   Gungor T ^d   Gerber, B ^a   Kuhne T ^e   Passweg, J R ^b,c   Gratwohl, A ^b   Tichelli, A ^b   Seger, R ^d   Schanz, U ^a   Halter, J ^b   Stussi, G ^f  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

CMV reactivation; Haploidentical transplantation; Immune reconstitution; T cell depletion

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; LEVOFLOXACIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; BACTERIAL INFECTION; BK VIRUS INFECTION; CANDIDIASIS; CD34 SELECTION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE INFECTION; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; LUNG ASPERGILLOSIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; SURVIVAL TIME; SWITZERLAND; T CELL DEPLETION; VIRUS REACTIVATION;

ADOLESCENT; ADSORPTION; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD19; ANTIGENS, CD3; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; NEUTROPHILS; RECURRENCE; RETROSPECTIVE STUDIES; SWITZERLAND; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891878992     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.132     Document Type: Article

References (36)

1. Passweg J, Baldomero H, Stern M, Bargetzi M, Ghielmini M, Leibundgut K et al. Hematopoietic stem cell transplantation in Switzerland: a comprehensive quality control report on centre effect. Swiss Med Wkly 2010; 140: 326-334.
2. Symons HJ, Fuchs EJ. Hematopoietic SCT from partially HLA-mismatched (HLAhaploidentical) related donors. Bone Marrow Transplant 2008; 42: 365-377.
3. Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant 2008; 41: 473-481.
4. Reisner Y, Martelli MF. From 'megadose' haploidentical hematopoietic stem cell transplants in acute leukemia to tolerance induction in organ transplantation. Blood Cells Mol Dis 2008; 40: 1-7.
5. Hagin D, Reisner Y. Haploidentical bone marrow transplantation in primary immune deficiency: stem cell selection and manipulation. Hematol Oncol Clin North Am 2011; 25: 45-62.
6. Koh L-P, Chao N. Haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42 (Suppl 1): S60-S63.
7. Kanda Y, Oshima K, Asano-Mori Y, Kandabashi K, Nakagawa M, Sakata-Yanagimoto M et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 2005; 79: 1351-1357.
8. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690-697.
9. Chakrabarti S, Hale G, Waldmann H. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here? Transplant Proc 2004; 36: 1225-1227.
10. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLAhaploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-650.
11. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
12. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
13. Kanda J, Chao NJ, Rizzieri DA. Haploidentical transplantation for leukemia. Curr Oncol Rep 2010; 12: 292-301.
14. Chalandon Y, Roosnek E, Mermillod B, Waelchli L, Helg C, Chapuis B. Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. Biol Blood Marrow Transplant 2006; 12: 102-110.
15. Spitzer T. Haploidentical Stem Cell Transplantation: The Always Present but Overlooked Donor. Hematology 2005; 2005: 390.
16. Lang P, Handgretinger R. Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transplant 2008; 42 (Suppl 2): S54-S59.
17. Federmann B, Hagele M, Pfeiffer M, Wirths S, Schumm M, Faul C et al. Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukemia 2011; 25: 121-129.
18. Chang Y-J, Zhao X-Y, Huo M-R, Xu L-P, Liu D-H, Liu K-Y et al. Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies. Am J Hematol 2011; 86: 227-230.
19. Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009; 113: 4771-4779.
20. Stern M, Ruggeri L, Mancusi A, Bernardo ME, de Angelis C, Bucher C et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008; 112: 2990-2995.
21. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010; 115: 3437-3446.
22. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
23. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574-3581.
24. Bethge WA, Faul C, Bornhauser M, Stuhler G, Beelen DW, Lang P et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis 2008; 40: 13-19.
25. Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000; 95: 3996-4003.
26. Lee SJ, Zahrieh D, Alyea EP, Weller E, Ho VT, Antin JH et al. Comparison of T-celldepleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood 2002; 100: 2697-2702.
27. Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 2012; 30: 3194-3201.
28. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864.
29. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942-2947.
30. Barge RMY, Starrenburg CWJ, Falkenburg JHF, Fibbe WE, Marijt EW, Willemze R. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath 'in the bag' as T-cell depletion: the Leiden experience. Bone Marrow Transplant 2006; 37: 1129-1134.
31. Lang P, Schumm M, Greil J, Bader P, Klingebiel T, Muller I et al. A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: preliminary results of a pilot study. Klin Padiatr 2005; 217: 334-338.
32. Chen X, Hale GA, Barfield R, Benaim E, Leung WH, Knowles J et al. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol 2006; 135: 524-532.
33. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotypemismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454.
34. Buhlmann L, Buser AS, Cantoni N, Gerull S, Tichelli A, Gratwohl A et al. Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT. Bone Marrow Transplant 2010; 46: 1357-1362.
35. Wendtner C-M, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 1093-1101.
36. Schmidt-Hieber M, Schwarck S, Stroux A, Ganepola S, Reinke P, Thiel E et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol 2010; 91: 877-885.